Medicare locks skin-substitute prices to 2023 data, blocks cost-based coverage denials
S. 2561 — Skin Substitute Access and Payment Reform Act of 2025 · Filed by Bill Cassidy (R-LA) · 2 cosponsors · Introduced Jul 31, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill reforms how Medicare pays for skin substitute products—advanced biological treatments for chronic wounds like diabetic ulcers. Starting January 1, 2026, instead of paying different amounts for different products, Medicare will pay a single volume-weighted average price based on 2023 billing data, adjusted annually for inflation. The bill also consolidates all skin substitutes into one billing code and prevents Medicare from denying coverage based solely on clinical evidence, requiring manufacturers to prove only safety (contamination, infection, serious adverse reactions), not comparative effectiveness.
Why we flagged it
The bill's core mechanism is standardizing Medicare reimbursement for skin substitutes via volume-weighted averaging, but it simultaneously restricts CMS's ability to differentiate products based on clinical evidence—a constraint that appears designed to protect manufacturers from comparative-effectiveness denials rather than to serve patient interests.
What the text implies
- By locking the payment baseline to Q4 2023 data and adjusting only for CPI, the bill prevents Medicare from repricing based on new clinical evidence, market competition, or cost-effectiveness studies—effectively freezing relative product valuations for years.
- The prohibition on denying coverage 'based solely on analysis of any clinical evidence' may prevent Medicare from withdrawing coverage for products later found to be inferior or unsafe, creating a one-way ratchet favoring incumbent manufacturers.
- Consolidating all skin substitutes into a single billing code obscures product-level utilization and cost data, making future cost-containment efforts more difficult and reducing transparency for policymakers and the public.
- Manufacturers are exempted from reporting average sales prices under section 1927, reducing price transparency and making it harder for Congress or CMS to detect price inflation or anti-competitive behavior.
- The bill's framing as 'cost containment' masks that it standardizes pricing upward to a volume-weighted average, which may increase total Medicare spending if lower-cost products were previously preferred.
Who it affects
Medicare beneficiaries with chronic wounds may benefit from simplified, standardized pricing that could reduce incentives for unnecessary expensive products and lower out-of-pocket costs. However, the volume-weighted average approach locks pricing to 2023 data and may reduce manufacturer innovation incentives, potentially limiting future product development. The ban on clinical-evidence-based coverage denials could also allow less effective products to remain covered at the same rate as proven a
Who stands to gain
- skin substitute product manufacturers
- advanced wound-care companies
- biological therapy producers
Named in the bill
Centers for Medicare & Medicaid Services (CMS), Medicare Part B, Social Security Act Section 1847A, FDA (sections 510, 513, 515, 505), Public Health Service Act Section 361, Integrated Data Repository, ASP Pricing File, AIG, FBK, FMAO, PFG, PRU
Where it stands
2 cosponsors: 2 Democrats.
- Jul 31, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Jul 31, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
13 lobbying clients named this bill on 19 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,990,618 in lobbying spend. A filing names 3 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 94% of bills with at least one filing.
Bill Cassidy, the sponsor, reported $1,329,254 in PAC receipts in the 2026 cycle.
- Accountable for Health, Inc. — $520,000 on 2 filings
- Smith & Nephew, Inc. — $490,000 on 1 filing
- National Association of Accountable Care Organizations — $276,869 on 2 filings
- Convatec, Inc. F/k/a Triad Life Sciences, Inc. — $170,000 on 2 filings
- Organogenesis Inc. — $150,000 on 2 filings
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 2, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Medicare locks skin-substitute prices to 2023 data, blocks cost-based coverage denials” QuorumCivic. https://share.quorumcivic.app/bill/119/s2561 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.